Ledipasvir + Sofosbuvir interactions
Checked as Ledipasvir + Sofosbuvir in this data source.
Full monograph for Ledipasvir + SofosbuvirCheck it against another medicine
Medicines
143 documented
| Medicine | Severity | Mechanism | Effect | Sources |
|---|---|---|---|---|
| Amiodarone Hydrochloridevia Sofosbuvir | Major | Others | Severe, life-threatening, symptomatic bradycardia has been reported during coadministration of amiodarone with ledipasvir-sofosbuvir or with sofosbuvir taken… | 8 sources — open the full entry |
| Apalutamidevia Ledipasvir, Sofosbuvir | Major | Absorption · Metabolism | Coadministration with inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral…2 documented mechanisms | 14 sources — open the full entry |
| Carbamazepinevia Sofosbuvir | Major | Absorption | Coadministration with potent inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting… | 5 sources — open the full entry |
| Colchicinevia Ledipasvir | Major | Absorption · Excretion | Coadministration with inhibitors of P-glycoprotein (P-gp) may significantly increase the serum concentrations of colchicine. The mechanism involves enhanced…2 documented mechanisms | 107 sources — open the full entry |
| Enzalutamidevia Sofosbuvir | Major | Absorption | Coadministration with inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral… | 11 sources — open the full entry |
| Fosphenytoin Sodiumvia Sofosbuvir | Major | Absorption | Coadministration with potent inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting… | 5 sources — open the full entry |
| Lorlatinibvia Sofosbuvir | Major | Absorption | Coadministration with inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral… | 11 sources — open the full entry |
| Morphine Sulfatevia Ledipasvir | Major | Absorption | Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of morphine and its risk of adverse effects, including… | 7 sources — open the full entry |
| Oxcarbazepinevia Sofosbuvir | Major | Absorption | Coadministration with inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral… | 11 sources — open the full entry |
| Phenobarbitalvia Sofosbuvir | Major | Absorption | Coadministration with potent inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting… | 5 sources — open the full entry |
| Phenytoin Sodiumvia Sofosbuvir | Major | Absorption | Coadministration with potent inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting… | 5 sources — open the full entry |
| Primidonevia Sofosbuvir | Major | Absorption | Coadministration with potent inducers of P-glycoprotein (P-gp) may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting… | 5 sources — open the full entry |
| Relugolixvia Ledipasvir | Major | Absorption | Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the… | 1 sources — open the full entry |
| Relugolix + Estradiol + Norethindronevia Ledipasvir | Major | Absorption | Coadministration with inhibitors of the P-glycoprotein (P-gp) efflux transporter may increase the plasma concentrations of relugolix, particularly when the… | 1 sources — open the full entry |
| Rifampicinvia Sofosbuvir | Major | Absorption · Metabolism | Coadministration with rifampin may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral agents that may be given… | 4 sources — open the full entry |
| Rifampicin + Isoniazidvia Sofosbuvir | Major | Absorption · Metabolism | Coadministration with rifampin may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral agents that may be given… | 4 sources — open the full entry |
| Rifampicin + Isoniazid + Pyrazinamide + Ethambutolvia Sofosbuvir | Major | Absorption · Metabolism | Coadministration with rifampin may significantly decrease the plasma concentrations of sofosbuvir and other direct-acting antiviral agents that may be given… | 4 sources — open the full entry |
| Venetoclaxvia Ledipasvir | Major | Absorption | Coadministration with P-glycoprotein (P-gp) inhibitors may increase the plasma concentrations of venetoclax, which is a substrate of this efflux transporter.2 documented mechanisms | 8 sources — open the full entry |
| Acarbosevia Ledipasvir, Sofosbuvir | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
| Afatinib Dimaleatevia Ledipasvir | Moderate | Distribution · Others | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of afatinib, which is a substrate of the efflux transporter.2 documented mechanisms | 5 sources — open the full entry |
| Alogliptin Benzoatevia Ledipasvir, Sofosbuvir | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
| Alpelisibvia Ledipasvir | Moderate | Excretion · Others | Coadministration of inhibitors of the breast cancer resistance protein (BCRP) transporter with alpelisib may increase the plasma concentrations and risk of…2 documented mechanisms | 5 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxidevia Ledipasvir | Moderate | Absorption | INTERVAL: Concurrent administration of ledipasvir with drugs that elevate gastric pH such as antacids may reduce its gastrointestinal absorption. Ledipasvir…4 documented mechanisms | 2 sources — open the full entry |
| Aluminium Hydroxide + Magnesium Hydroxide + Simethiconevia Ledipasvir | Moderate | Absorption | INTERVAL: Concurrent administration of ledipasvir with drugs that elevate gastric pH such as antacids may reduce its gastrointestinal absorption. Ledipasvir…4 documented mechanisms | 2 sources — open the full entry |
| Amlodipine Besilate + Atorvastatinvia Ledipasvir | Moderate | Metabolism | Coadministration of HMG-CoA reductase inhibitors (statins) with HCV NS5A/NS5B inhibitors, such as ledipasvir, may significantly increase the plasma…2 documented mechanisms | 16 sources — open the full entry |
| Apixabanvia Ledipasvir | Moderate | Metabolism | Coadministration with inhibitors of CYP450 3A4 and/or P-glycoprotein (P-gp) may increase the plasma concentrations of apixaban, which is a substrate of both…2 documented mechanisms | 5 sources — open the full entry |
| Apremilastvia Ledipasvir | Moderate | Absorption · Metabolism | Coadministration with ledipasvir may increase the plasma concentrations of orally administered drugs that are substrates of the P-glycoprotein (P-gp) and/or…2 documented mechanisms | 2 sources — open the full entry |
| Armodafinilvia Ledipasvir | Moderate | Absorption · Metabolism | Coadministration with ledipasvir may increase the plasma concentrations of orally administered drugs that are substrates of the P-glycoprotein (P-gp) and/or…2 documented mechanisms | 2 sources — open the full entry |
| Artesunatevia Ledipasvir | Moderate | Absorption · Metabolism | Coadministration with ledipasvir may increase the plasma concentrations of orally administered drugs that are substrates of the P-glycoprotein (P-gp) and/or…2 documented mechanisms | 2 sources — open the full entry |
| Atorvastatin + Ezetimibevia Ledipasvir | Moderate | Metabolism | Coadministration of HMG-CoA reductase inhibitors (statins) with HCV NS5A/NS5B inhibitors, such as ledipasvir, may significantly increase the plasma…2 documented mechanisms | 16 sources — open the full entry |
| Atorvastatin Calciumvia Ledipasvir | Moderate | Metabolism | Coadministration of HMG-CoA reductase inhibitors (statins) with HCV NS5A/NS5B inhibitors, such as ledipasvir, may significantly increase the plasma…2 documented mechanisms | 16 sources — open the full entry |
| Betrixabanvia Ledipasvir | Moderate | Absorption · Excretion | Coadministration with inhibitors of P-glycoprotein (P-gp) may increase the plasma concentrations of betrixaban, which is a substrate of the efflux transporter.2 documented mechanisms | 5 sources — open the full entry |
| Biphasic Insulin Aspartvia Ledipasvir, Sofosbuvir | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
| Bromocriptine Mesylatevia Ledipasvir, Sofosbuvir | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
| Calcium acetate + Magnesium carbonatevia Ledipasvir | Moderate | Absorption | Concurrent administration of ledipasvir with drugs that elevate gastric pH such as antacids may reduce its gastrointestinal absorption. Ledipasvir exhibits…2 documented mechanisms | 2 sources — open the full entry |
| Calcium Carbonatevia Ledipasvir | Moderate | Absorption | INTERVAL: Concurrent administration of ledipasvir with drugs that elevate gastric pH such as antacids may reduce its gastrointestinal absorption. Ledipasvir…2 documented mechanisms | 2 sources — open the full entry |
| Calcium Lactate Gluconate + Calcium Carbonate + Vitamin Cvia Ledipasvir | Moderate | Absorption | INTERVAL: Concurrent administration of ledipasvir with drugs that elevate gastric pH such as antacids may reduce its gastrointestinal absorption. Ledipasvir…2 documented mechanisms | 2 sources — open the full entry |
| Calcium Lactate Gluconate + Calcium Carbonate + Vitamin C + Vitamin D3via Ledipasvir | Moderate | Absorption | INTERVAL: Concurrent administration of ledipasvir with drugs that elevate gastric pH such as antacids may reduce its gastrointestinal absorption. Ledipasvir…2 documented mechanisms | 2 sources — open the full entry |
| Calcium Lactate Gluconate + Calcium Carbonate + Vitamin D3via Ledipasvir | Moderate | Absorption | INTERVAL: Concurrent administration of ledipasvir with drugs that elevate gastric pH such as antacids may reduce its gastrointestinal absorption. Ledipasvir…2 documented mechanisms | 2 sources — open the full entry |
| Calcium Lactate Gluconate + Calcium Carbonate + Vitamin D3 + Multimineralsvia Ledipasvir | Moderate | Absorption | INTERVAL: Concurrent administration of ledipasvir with drugs that elevate gastric pH such as antacids may reduce its gastrointestinal absorption. Ledipasvir…2 documented mechanisms | 2 sources — open the full entry |
| Canagliflozin Hemihydratevia Ledipasvir, Sofosbuvir | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
| Ceritinibvia Ledipasvir | Moderate | Absorption · Metabolism | Coadministration with ledipasvir may increase the plasma concentrations of orally administered drugs that are substrates of the P-glycoprotein (P-gp) and/or…2 documented mechanisms | 2 sources — open the full entry |
| Cyclosporine (Oral)via Ledipasvir, Sofosbuvir | Moderate | Absorption · Metabolism | Coadministration with ledipasvir may increase the plasma concentrations of orally administered drugs that are substrates of the P-glycoprotein (P-gp) and/or…3 documented mechanisms | 16 sources — open the full entry |
| Dabigatran Etexilate Mesylatevia Ledipasvir | Moderate | Metabolism | Coadministration with ledipasvir may increase the plasma concentrations of orally administered drugs that are substrates of the P-glycoprotein (P-gp) and/or… | 1 sources — open the full entry |
| Dapagliflozin Propanediolvia Ledipasvir, Sofosbuvir | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
| Dexlansoprazolevia Ledipasvir | Moderate | Absorption | Coadministration of ledipasvir with proton pump inhibitors may reduce its gastrointestinal absorption. Ledipasvir exhibits pH-dependent solubility, with…2 documented mechanisms | 6 sources — open the full entry |
| Digoxinvia Ledipasvir | Moderate | Absorption | Coadministration with ledipasvir may increase the oral bioavailability of digoxin. The proposed mechanism is ledipasvir inhibition of the…2 documented mechanisms | 4 sources — open the full entry |
| Dulaglutidevia Ledipasvir, Sofosbuvir | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
| Elacestrantvia Ledipasvir, Sofosbuvir | Moderate | Absorption | Coadministration with elacestrant may increase the plasma concentrations of drugs that are substrates of P-glycoprotein (P-gp) and/or breast cancer resistance…2 documented mechanisms | 1 sources — open the full entry |
| Empagliflozinvia Ledipasvir, Sofosbuvir | Moderate | Synergy | Clearance of hepatitis C virus (HCV) infection with direct acting antiviral agents (DAAs) may lead to changes in hepatic function which may result in altered…2 documented mechanisms | 11 sources — open the full entry |
Conditions
Conditions in which Ledipasvir + Sofosbuvir needs care, as documented in this source.
IMMUNE SUPPRESSION
MajorHBV reactivation has been reported during or after completion of HCV direct-acting antiviral therapy in HCV/HBV-coinfected patients who were not receiving HBV antiviral therapy; some cases resulted in fulminant hepatitis, hepatic failure, and death. Cases have been reported in hepatitis B surface antigen (HBsAg)-positive patients and patients with serologic evidence of resolved HBV infection (i.e., HBsAg negative and hepatitis B core antibody [anti-HBc] positive). HBV reactivation has also been reported in patients using certain immunosuppressant or chemotherapeutic agents; risk of HBV reactivation associated with HCV direct-acting antiviral therapy may be increased in these patients. All patients should be tested for evidence of current or prior HBV infection by measuring HBsAg and anti-HBc before starting HCV direct-acting antiviral therapy. Patients with serologic evidence of current or prior HBV infection should be monitored for clinical and laboratory signs of hepatitis flare or HBV reactivation during HCV therapy and posttherapy follow-up; appropriate patient management for HBV infection should be started as clinically indicated.
7 sources
- "Product Information. Sovaldi (sofosbuvir)." Gilead Sciences (2013):
- "Product Information. Harvoni (ledipasvir-sofosbuvir)." Gilead Sciences (2014):
- "Product Information. Viekira Pak (dasabuvir/ombitasvir/paritaprev/ritonav)." AbbVie US LLC (2022):
- "Product Information. Zepatier (elbasvir-grazoprevir)." Merck & Co., Inc (2016):
- "Product Information. Epclusa (sofosbuvir-velpatasvir)." Gilead Sciences (2016):
- "Product Information. Vosevi (sofosbuvir/velpatasvir/voxilaprevir)." Gilead Sciences (2017):
- "Product Information. Mavyret (glecaprevir-pibrentasvir)." Abbott Pharmaceutical (2017):
Hepatic Insufficiency
ModerateSofosbuvir is extensively metabolized in the liver. The safety and efficacy of sofosbuvir as a single agent have not been established in patients with decompensated cirrhosis. No dosage adjustment is required for patients with mild, moderate or severe hepatic impairment (Child-Pugh Class A, B or C).
1 source
- "Product Information. Sovaldi (sofosbuvir)." Gilead Sciences (2013):
Kidney Diseases
ModerateThe safety and efficacy of sofosbuvir as a single agent have not been established in patients with severe renal impairment (eGFR less than 30 mL/min/1.73m2) or ESRD requiring hemodialysis. No dosage recommendation can be given for patients with severe renal impairment or ESRD. No dosage adjustment is necessary for patients with mild or moderate renal impairment.
1 source
- "Product Information. Sovaldi (sofosbuvir)." Gilead Sciences (2013):